2021 Worldwide Immunology Partnering Deals Insights – Leading Immunology Deals by Value Since 2014 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Immunology Partnering 2014-2021: Deal Trends, Players and Financials” report has been added to ResearchAndMarkets.com’s offering.

Global Immunology Partnering 2014 to 2021 provides the full collection of Immunology disease deals signed between the world’s pharmaceutical and biotechnology companies since 2014.

• Trends in Immunology partnering deals
• Financial deal terms for headline, upfront and royalty by stage of development
• Immunology partnering agreement structure
• Immunology partnering contract documents
• Top Immunology deals by value
• Most active Immunology dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Immunology disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Immunology deals.

The report presents financial deal terms values for Immunology deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

Global Immunology Partnering 2014 to 2021 includes:

• Trends in Immunology dealmaking in the biopharma industry since 2014
• Access to headline, upfront, milestone and royalty data
• Access to hundreds of Immunology deal contract documents
• Comprehensive access to over 850 Immunology deal records
• The leading Immunology deals by value since 2014
• Most active Immunology dealmakers since 2014

The report includes deals for the following indications: AIDS, Allergy, Anaphylactic shock, Graft versus host disease, Inflammation, Other autoimmune, Scleroderma, Systemic lupus erythematosus, plus other immunology indications.

In Global Immunology Partnering 2014 to 2021, available deals and contracts are listed by:

• Headline value
• Upfront payment value
• Royalty rate value
• Stage of development at signing
• Deal component type
• Technology type
• Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Immunology Partnering 2014-2021 report provides comprehensive access to available deals and contract documents for over 850 immunology deals.

Key Benefits

Global Immunology Partnering 2014 to 2021 provides the reader with the following key benefits:

• In-depth understanding of Immunology deal trends since 2014
• Access Immunology deal headline, upfront, milestone and royalty data
• Research hundreds of actual contracts between Immunology partner companies
• Comprehensive access to over 850 links to actual Immunology deals entered into by the world’s biopharma companies
• In-depth review of Immunology deals entered into by the top 25 most active dealmakers
• Benchmark the key deal terms companies have agreed in previous deals
• Identify key terms under which companies partner Immunology opportunities
• Uncover companies actively partnering Immunology opportunities

The initial chapters of this report provide an orientation of Immunology dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Immunology dealmaking since 2014 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Immunology deals since 2014. Deals are listed by headline value. The chapter includes the top 25 most active Immunology dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Immunology deals since 2014 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Immunology partnering deals by specific Immunology target announced since 2014. The chapter is organized by specific Immunology therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Companies Mentioned

• University of Dundee
• Endo Pharmaceuticals
• Integral Molecular
• 4D Pharma
• Quest PharmaTech
• Lead Pharma
• Kineta
• Rabin Medical Center (Beilinson Hospital)
• Institute of Child Health
• Grunenthal
• EMD Serono
• Hualan Genetic
• Neovii Pharmaceuticals
• Jnana Therapeutics
• Fred Hutchinson Cancer Research Center
• Memorial Sloan Kettering Cancer Center
• Enterome Bioscience
• Ewopharma
• Cell Mogrify
• Immatics US
• Feldan Therapeutics
• Science Exchange
• GT Biopharma
• Medical University of South Carolina
• Tetra Bio-Pharma
• The Hospital for Sick Children
• Medentech
• OncoImmune
• Innovent Biologics
• French National Genotyping Center
• GeoVax
• AirWare Labs
• European Bioinformatics Institute
• InflamaCORE
• Centurion
• Advanz Pharma
• Oslo University Hospital
• Pinnacle Clinical Research Center
• Abbott Laboratories
• National University of Singapore
• MediGene
• Repurpose.AI
• EVOQ Therapeutics
• Institute for Bioscience and Biotechnology Research
• Abreos Biosciences
• Elpis Biomed
• Nature Technology
• R-Pharm
• AbCellera
• The Parker Institute For Cancer Immunotherapy

For more information about this report visit https://www.researchandmarkets.com/r/nyuqy0

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900